Thrombotic thrombocytopenic purpura in children

Current Opinion in Pediatrics

Volumn 25, Issue 2, 2013, Pages 216-224

  Loirat, Chantal ^a,b   Coppo, Paul ^b,c   Veyradier, Agnès ^b,d,e  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b Ctr Natl de Ref des Antibiot   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

ADAMTS13 deficiency; Plasma therapy; Recombinant ADAMTS13; Thrombotic thrombocytopenic purpura; Upshaw Schulman syndrome

Indexed keywords

ACETYLCYSTEINE; APTAMER; ECULIZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NANOBODY; PREDNISONE; RECOMBINANT ENZYME; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA; ADD ON THERAPY; AMINO TERMINAL SEQUENCE; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL FEATURE; CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA; DIAGNOSTIC VALUE; DISEASE COURSE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME ASSAY; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; JAUNDICE; LABORATORY TEST; NONHUMAN; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ADAM PROTEINS; CHILD; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS;

EID: 84875382509     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835e7888     Document Type: Review

References (73)

1. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
3. Sadler JE. von Willebrand factor: Two sides of a coin. J Thromb Haemost 2005; 3:1702-1709.
4. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87:4223-4234.
5. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87:4235-4244.
6. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factorcleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276:41059-44163.
7. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-494.
8. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 2001; 74:101-108.
9. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91:1-19.
10. Loirat C, Fré meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6:60.
11. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012; 41 (3 Pt 2):e115-e135.
12. Loirat C, Girma JP, Desconclois C, et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol 2009; 24:19-29.
13. Yagi H, Matsumoto M, Fujimura Y. Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency. Presse Med 2012; 41:e137-e155.
14. Lotta LA,WuHM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120:440-448.
15. Robson WL, Tsai HM. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics 2002; 109:322-325.
16. Ashida A, Nakamura H, Yoden A, et al. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): Important discrimination from Upshaw-Schulman syndrome. Am J Hematol 2002; 71:318-322.
17. Horton TM, Stone JD, Yee D, et al. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol 2003; 25:336-339.
18. Schneppenheim R, Budde U, Hassenpflug W, Obser T. Severe ADAMTS-13 deficiency in childhood. Semin Hematol 2004; 41:83-89.
19. Curtillet C, Poullin P, Doré E, et al. Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura. Arch Pediatr 2006; 13:1521-1524.
20. Albaramki JH, Teo J, Alexander SI. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol 2009; 24:1749-1752.
21. McDonald V, Liesner R, Grainger J, et al. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: Clinical management and the use of ADAMTS 13 assays. Blood Coagul Fibrinolysis 2010; 21:245-250.
22. Sato A, Hoshi Y, Onuma M, et al. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13. Pediatr Hematol Oncol 2010; 27:53-58.
23. Harambat J, Lamireau D, Delmas Y, et al. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review. Pediatr Crit Care Med 2011; 12:e90-e93.
24. Jayabose S, Dunbar J, Nowicki TS, et al. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. Pediatr Hematol Oncol 2011; 28:167-172.
25. Narayanan P, Jayaraman A, Rustagi RS, et al. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange. Int J Hematol 2012; 96:122-124.
26. Espié E, Grimont F,Mariani-Kurkdjian P, et al. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France 1996-2006. Pediatr Infect Dis J 2008; 27:595-601.
27. Pennington H. Escherichia coli O157. Lancet 2010; 376:1428-1435.
28. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013. doi: 10.2215/CJN. 04760512. [Epub ahead of print]
29. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Complement blockade in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561-2563.
30. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657.
31. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:631-640.
32. Palla R, Valsecchi C, Bajetta M, et al. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost 2011; 105:381-385.
33. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100.
34. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323-335.
35. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 2012; 41:e163-e176.
36. Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10:1792-1801.
37. Deschê nes G, Veyradier A, Cloarec S, et al. Plasma therapy in von Willebrand factor protease deficiency. Pediatr Nephrol 2002; 17:867-870.
38. Loirat C, Veyradier A, Girma JP, et al. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 2006; 32:90-97.
39. George JN. Forecasting the future for patients with hereditary TTP. Blood 2012; 120:243-244.
40. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw- Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119:588-597.
41. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107:118-125.
42. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31:11-19.
43. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115:2752-2761.
44. Noris M, Bucchioni S, Galbusera M, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS 13 deficiency and renal involvement. J Am Soc Nephrol 2005; 16:1177-1183.
45. Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81:8-13.
46. Thampi S, Salmi D, Imashuku S, et al. Thrombotic thrombocytopenic purpura in a child with systemic lupus erythematosus. J Pediatr Hematol Oncol 2011; 33:221-223.
47. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: Correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142:819-826.
48. Lotta LA, Mariani M, Consonni D, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151:488-494.
49. Benhamou Y, Assié C, Boelle PY, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency- associated idiopathic thrombotic thrombocytopenic purpura: The French TMA Reference Center experience. Haematologica 2012; 97:1181-1186.
50. Michon B, Moghrabi A, Winikoff R, et al. Complications of apheresis in children. Transfusion 2007; 47:1837-1842.
51. George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87 (Suppl 1): S88-91.
52. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106:1932-1937.
53. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451-461.
54. Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: A report of four cases and a systematic review of the literature. Eur J Haematol 2009; 83:365-372.
55. Caramazza D, Quintini G, Abbene I, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura: haemolytic uraemic syndrome. Blood Transfus 2010; 8:203-210.
56. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40:104-111.
57. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746-1753.
58. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109:2815-2822.
59. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141:651-658.
60. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93:232-239.
61. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500-1511.
62. Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10:1556-1565.
63. Mannucci PM, Franchini M. Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura. Presse Med 2012; 41:e157-e162.
64. Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: Correction of symptoms by recombinant human ADAMTS13. Blood 2012; 119:6128-6135.
65. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9:936-944.
66. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 12:593-603.
67. Cataland SR, Peyvandi F, Mannucci PM, et al. Initial experience from a doubleblind placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87:430-432.
68. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012; 120:3603-3610.
69. Feys HB, Roodt J, Vandeputte N, et al. Inhibition of von Willebrand factorplatelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012; 120:3611-3614.
70. Jian C, Xiao J, Gong L, et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119:3836-3843.
71. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93:443-452.
72. Ré ti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10:791-798.
73. Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157:772-774.